Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Subscription
to La Merie Publishing’s proprietary Antibody Database provides online
access to information about more than 2,400 project entries for
therapeutic antibodies on the market and in research & development.
Pre-established and free search functions allow to identify antibodies
according to their
To Read The Complete Report with TOC:-
· Technology (e.g. antibody-drug conjugate, bispecific, isotype, phage display)
· Target (e.g. Her2, CD20, TNF, PD-1/PD-L1)
· Pipelines (selected by target, therapeutic area, company, technology)
· Sales (for marketed antibodies)
· R&D Phase (clinical phases, market, preclinical)
· Territory (countrywise)
· Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
· Drug Code/Name (for individual molecules)
Each
project is specified for its Target, Therapeutic Area and R&D
Phase. Use of the R&D database of therapeutic antibodies is
intuitive. Data sets of interest can be printed and exported as reports
in Excel or Word format. Projects are being updated continuously. The
R&D history of each project with online references of information
sources can be viewed and printed. Sales figures of major therapeutic
antidoies on the market are provided.
To Buy a Copy Of This Report:-
An
advanced search function allows to combine search parameters. A scroll
down menu for predefined targets and technologies conveniently selects
projects of interest. By clicking on column heads of the project list,
projects can be arranged in ascending or descending alphabetical or
numerical order, e.g. for phase or company name.
Special Focus of the Database:
· Antibody-Drug Conjugates
· Bispecific Antibodies
· Biosimilar and Biosuperior Antibodies
Contact:-
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
